The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.
The grant will fund a collaboration investigating whether genomic signatures and other biomarkers can be used in clinical diagnosis and monitoring of kidney cancer.
The collaborators are each providing funding and samples, and plan to study about 100 patients with a subset of Castleman disease to identify biomarkers.
Cancer Genetics will help analyze biomarkers to identify response patient populations, as well as reflect the mechanism of action of Effector's eFT508.
New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
The Genomics Evidence Neoplasia Information Exchange aims to provide insights through the analysis of data from tens if not hundreds of thousands of patient results.
BMS has provided funding to the diagnostic company to support build-out of its new lab and development of its platform, which they hope can identify new biomarkers for Opdivo.
